A detailed history of Raymond James & Associates transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 190,505 shares of RVMD stock, worth $8.25 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
190,505
Previous 74,370 156.16%
Holding current value
$8.25 Million
Previous $2.89 Million 199.06%
% of portfolio
0.01%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$36.92 - $47.94 $4.29 Million - $5.57 Million
116,135 Added 156.16%
190,505 $8.63 Million
Q2 2024

Jul 19, 2024

BUY
$30.14 - $40.68 $1.49 Million - $2 Million
49,275 Added 196.35%
74,370 $2.89 Million
Q1 2024

Apr 22, 2024

SELL
$26.56 - $33.55 $105,868 - $133,730
-3,986 Reduced 13.71%
25,095 $808,000
Q4 2023

Jan 16, 2024

BUY
$18.35 - $34.12 $533,636 - $992,243
29,081 New
29,081 $834,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.